Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Cedar Pollen Allergy - Pipeline Review, H2 2016 - Research and Markets

Research and Markets
Posted on: 27 Oct 16

Research and Markets has announced the addition of the "Cedar Pollen Allergy - Pipeline Review, H2 2016" report to their offering.

Cedar Pollen Allergy pipeline therapeutics constitutes close to 8 molecules. Out of which approximately 7 molecules are developed by Companies and remaining by the Universities Institutes. Our latest report Cedar Pollen Allergy - Pipeline Review, H2 2016, outlays comprehensive information on the therapeutics under development for Cedar Pollen Allergy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

Treatment includes antihistamines and decongestants. The molecules developed by Companies in Pre-Registration, Phase I, Preclinical and Discovery stages are 2, 2, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II stages comprises 1 molecules, respectively.

Furthermore, this report also reviews of key players involved in therapeutic development for Cedar Pollen Allergy and features dormant and discontinued projects.

Key Topics Covered:

  1. Introduction
  2. Cedar Pollen Allergy Overview
  3. Therapeutics Development
  4. Pipeline Products for Cedar Pollen Allergy - Overview
  5. Pipeline Products for Cedar Pollen Allergy - Comparative Analysis
  6. Cedar Pollen Allergy - Therapeutics under Development by Companies
  7. Cedar Pollen Allergy - Therapeutics under Investigation by Universities/Institutes
  8. Cedar Pollen Allergy Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Cedar Pollen Allergy - Products under Development by Companies
  13. Cedar Pollen Allergy - Products under Investigation by Universities/Institutes
  14. Cedar Pollen Allergy - Companies Involved in Therapeutics Development
  • ALK-Abello A/S
  • Astellas Pharma Inc.
  • Circassia Pharmaceuticals Plc
  • Immunomic Therapeutics, Inc.
  • Japan Tobacco Inc.
  • REGiMMUNE Corporation

For more information about this report visit

View source version on

Business Wire

Last updated on: 27/10/2016

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.